Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT04191135
Brief Title: Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

First Submitted : December 5, 2019
First Submitted that Met QC Criteria : December 5, 2019
First Posted : December 9, 2019

Last Update Submitted that Met QC Criteria : June 3, 2021
Last Update Posted : June 4, 2021